NASDAQ:ALLO

Allogene Therapeutics Stock Forecast, Price & News

$32.86
+0.71 (+2.21 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$31.56
Now: $32.86
$32.91
50-Day Range
$29.58
MA: $34.92
$39.02
52-Week Range
$24.73
Now: $32.86
$55.00
Volume554,520 shs
Average Volume859,343 shs
Market Capitalization$4.62 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.28
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALLO
CUSIPN/A
CIKN/A
Phone650-457-2700
Employees264
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.16 per share

Profitability

Net Income$-184,590,000.00

Miscellaneous

Market Cap$4.62 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable

Headlines

ALLO Crosses Below Key Moving Average Level
March 23, 2021 |  nasdaq.com
Why Novartis, Seelos Therapeutics And More Are Moving Today
January 26, 2021 |  markets.businessinsider.com
Is ALLO A Good Stock To Buy According To Hedge Funds?
December 19, 2020 |  finance.yahoo.com
First Week of ALLO August 2021 Options Trading
December 18, 2020 |  nasdaq.com
See More Headlines

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

760th out of 2,021 stocks

Biological Products, Except Diagnostic Industry

103rd out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$32.86
+0.71 (+2.21 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALLO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions

Is Allogene Therapeutics a buy right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Allogene Therapeutics stock.
View analyst ratings for Allogene Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Allogene Therapeutics?

Wall Street analysts have given Allogene Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Allogene Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Allogene Therapeutics' next earnings date?

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Allogene Therapeutics
.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) posted its quarterly earnings results on Wednesday, February, 24th. The company reported ($0.53) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.56) by $0.03.
View Allogene Therapeutics' earnings history
.

How has Allogene Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALLO shares have increased by 31.2% and is now trading at $32.86.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ALLO?

16 analysts have issued 12-month price targets for Allogene Therapeutics' stock. Their forecasts range from $41.00 to $70.00. On average, they expect Allogene Therapeutics' share price to reach $52.08 in the next year. This suggests a possible upside of 58.5% from the stock's current price.
View analysts' price targets for Allogene Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Allogene Therapeutics' key executives?

Allogene Therapeutics' management team includes the following people:
  • Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS, Co-Founder & Exec. Chairman (Age 72, Pay $664k)
  • Dr. David D. Chang M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 61, Pay $1.21M)
  • Mr. Joshua A. Kazam, Co-Founder & Director (Age 44, Pay $603.9k)
  • Dr. Eric Thomas Schmidt Ph.D., Chief Financial Officer (Age 51, Pay $612k)
  • Dr. Alison Moore Ph.D., Chief Technical Officer (Age 53, Pay $612k)
  • Dr. Rafael G. Amado, Chief Medical Officer and Exec. VP of R&D (Age 57, Pay $442.56k)
  • Ms. Barbra Sasu, Chief Scientific Officer
  • Mr. Veer Bhavnagri, Gen. Counsel & Compliance Officer (Age 38)
  • Ms. Christine Cassiano, Chief Communications Officer
  • Mr. David M. Tanen J.D., Sec. (Age 50)

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics CEO David Chang on Glassdoor.com. David Chang has an approval rating of 100% among Allogene Therapeutics' employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Allogene Therapeutics' key competitors?

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends for Allogene Therapeutics
.

Which institutional investors are selling Allogene Therapeutics stock?

ALLO stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Allogene Therapeutics company stock in the last year include Alison Moore, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Rafael Amado, and Veer Bhavnagri.
View insider buying and selling activity for Allogene Therapeutics
or view top insider-selling stocks.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $32.86.

How much money does Allogene Therapeutics make?

Allogene Therapeutics has a market capitalization of $4.62 billion. The company earns $-184,590,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.

How many employees does Allogene Therapeutics have?

Allogene Therapeutics employs 264 workers across the globe.

What is Allogene Therapeutics' official website?

The official website for Allogene Therapeutics is www.allogene.com.

Where are Allogene Therapeutics' headquarters?

Allogene Therapeutics is headquartered at 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.